Company Encyclopedia
View More
name
Evommune
EVMN.US
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC.
1.945 T
EVMN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Buy" from Analysts

    Evommune, Inc. (NYSE:EVMN) has received a consensus recommendation of "Buy" from five analysts. The average 1-year target price is $39.33. Cantor Fitzgerald, Morgan Stanley, Evercore ISI, and Leerink Partners have all issued positive ratings, with target prices ranging from $36 to $42. Evommune is a clinical-stage biotechnology company focusing on therapies for chronic inflammatory diseases such as CSU, AD, and UC.

    Market Beat·
    US
    EVMN
    +0.34%
    Market Beat·
    US
    EVMN
    +0.34%

    LSP 7 Cooperative UA Reports Acquisition of Common Shares in Evommune Inc

    LSP 7 Cooperative UA has acquired common shares in Evommune Inc. (EVMN), as reported in a recent SEC Form 4 filing. The filing is accessible through the provided link. This news was generated by Public Technologies (PUBT) and is for informational purposes only, not to be considered as financial, investment, or legal advice. Evommune Inc. is responsible for the original content published via EDGAR on November 12, 2025.

    Reuters·
    US
    EVMN
    +0.34%
    Reuters·
    US
    EVMN
    +0.34%

    Dir Verduyn-van Weegen Buys 1,562,500 ($25M) Of Evommune Inc [EVMN]

    Verduyn-van Weegen Felice Isabel Director and Beneficial Owner of Evommune Inc [EVMN] filed a Form 4 on November 12, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/7/25TransactionPurchaseShares1,562,500Price$16.00Value$25,000,000Ending Holdings: 4,929,633 - IndirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    EVMN
    +0.34%
    Reuters·
    US
    EVMN
    +0.34%

    NYSE provides pre-market update; Evommune rises in debut. Kristen Scholer reports market insights.

    On November 7, 2025, the New York Stock Exchange (NYSE) shared its daily pre-market report from the NYSE Trading Floor. The update offers valuable market insights for traders before the start of the trading session. Kristen Scholer presented the pre-market update, providing essential information on market trends and conditions. Stay informed with the latest NYSE Pre-market report for key data to guide your trading decisions each day.

    Unusual Whales·
    US
    EVMN
    +0.34%
    Unusual Whales·
    US
    EVMN
    +0.34%

    BUZZ-Evommune surges in NYSE debut after $150 million IPO

    Evommuneshares surged 26.1% in their NYSE debut, opening at $17.25 compared to the $16 IPO price, and last trading up 19.8% at $19.18. The company raised $150 million by selling approximately 9.4 million shares within the $15-$17 range. Based in Palo Alto, California, Evommune focuses on therapies for chronic inflammatory diseases and has two mid-stage treatments, EVO756 and EVO301. This marks the third significant U.S. biotech IPO since September, signaling a resurgence in drug developer IPOs after a prolonged freeze.

    Reuters·
    US
    EVMN
    +0.34%
    Reuters·
    US
    EVMN
    +0.34%
    © 2025 Longbridge｜Disclaimer